China's National Medical Products Administration announced on June 1 that it has approved the market entry of 21 medicines for children this year, with about a third prioritized for accelerated entry.
In recent years, the administration has increased its policy support for the research and development (R&D), approval, and production of medicines for children, resulting in a growing number of market entry approvals.
Statistics show that since 2019, the administration has approved 271 medicines for children.
The administration has pledged to implement greater preferential policies to facilitate the review and approval of medicines for children and to intensify the protection of related intellectual property rights.
It has also pledged efforts to providing more technological guidance to R&D companies, ensuring that special requirements, such as safety and suitability for children, are fully considered in R&D processes.
掃一掃在手機(jī)打開當(dāng)前頁  |
